Clinical Advisory Board established
Arovella is pleased to announce the appointment of three key opinion leaders and clinical oncologists to establish its Clinical Advisory Board (CAB).
The CAB will provide expert clinical insight and strategic advice focusing on CD19-positive haematological malignancies (blood cancers), as the Company looks to file its IND and commence its first-in-human phase 1 clinical trial. The members that will be appointed to Arovella’s CAB are:
Dr Salvatore Fiorenza, Deputy Director and Cell Therapy Lead at Epworth Healthcare;
Professor Sattva Neelapu, Professor and Deputy Chair at the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center; and
Dr Debora Barton, a Medical Oncologist who is also currently a Non-executive Director at Arovella.
Each member has been carefully selected, due to their experience working with cell therapies in early-stage clinical trials.